2. Search Result
Search Result
Results for "

necrosome

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100573
    Necrosulfonamide
    105+ Cited Publications

    		 Mixed Lineage Kinase Necroptosis Inflammation/Immunology Cancer
    Necrosulfonamide, a necroptosis and gasdermin D inhibitor, selectively targets (MLKL). Necrosulfonamide prevents the MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a key substrate of RIP3 in the induction of necrosis .
    Necrosulfonamide
  • HY-100573S
    Necrosulfonamide-d4

    		Isotope-Labeled Compounds Mixed Lineage Kinase Necroptosis Inflammation/Immunology Cancer
    Necrosulfonamide-d4 is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide, a necroptosis and gasdermin D inhibitor, selectively targets (MLKL). Necrosulfonamide prevents the MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a key substrate of RIP3 in the induction of necrosis .
    Necrosulfonamide-d4
  • HY-100573A
    (E/Z)-Necrosulfonamide

    		Mixed Lineage Kinase Necroptosis Inflammation/Immunology Cancer
    (E/Z)-Necrosulfonamide is a racemic compound of Necrosulfonamide (HY-100573). Necrosulfonamide, a necroptosis and gasdermin D inhibitor, selectively targets (MLKL). Necrosulfonamide prevents the MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a key substrate of RIP3 in the induction of necrosis .
    (E/Z)-Necrosulfonamide
  • HY-14909
    Bardoxolone
    15+ Cited Publications

    CDDO; RTA 401

    		 Keap1-Nrf2 Necroptosis SARS-CoV Virus Protease Infection Cardiovascular Disease Inflammation/Immunology
    Bardoxolone (RTA 401; CDDO) is an orally active activator of nuclear regulatory factor (NRf-2) and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone inhibits SARS-CoV-2 3CL protease with an EC50 value of 0.43 μM in vero cells. Bardoxolone also inhibits necroptosis in HT-29 cells with an EC50 value of 1.30 μM by blocking necrosome formation through inhibiting phosphorylation of RIPK1 and RIPK3. Bardoxolone can be used in research on COVID-19, TNF-induced systemic inflammatory response syndrome (SIRS), and cerebral ischemia-reperfusion injury .
    Bardoxolone
  • HY-173185
    RIP1-IN-1

    		RIP kinase Necroptosis Inflammation/Immunology
    RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (Kd: 110 nM). RIP1-IN-1 exhibits strong anti-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury .
    RIP1-IN-1
  • HY-14909R
    Bardoxolone (Standard)

    CDDO (Standard); RTA 401 (Standard)

    		 Keap1-Nrf2 Necroptosis SARS-CoV Virus Protease Infection Cardiovascular Disease Inflammation/Immunology
    Bardoxolone (Standard) is the analytical standard of Bardoxolone (HY-14909). This product is intended for research and analytical applications. Bardoxolone is an orally active activator of nuclear regulatory factor (NRf-2) and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone inhibits SARS-CoV-2 3CL protease with an EC50 value of 0.43 μM in vero cells. Bardoxolone also inhibits necroptosis in HT-29 cells with an EC50 value of 1.30 μM by blocking necrosome formation through inhibiting phosphorylation of RIPK1 and RIPK3. Bardoxolone can be used in research on COVID-19, TNF-induced systemic inflammatory response syndrome (SIRS), and cerebral ischemia-reperfusion injury .
    Bardoxolone (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: